Hepatitis Forums
Advanced Liver Disease Main Forums => Advanced Liver Disease => Topic started by: Hep Editors on March 18, 2019, 10:32:27 am
-
On January 14, the Food and Drug Administration approved the multikinase inhibitor Cabometyx (cabozantinib) for people with previously treated hepatocellular carcinoma (HCC), the most common type of liver cancer.
This approval was based on a clinical trial showing that Cabometyx improved both progression-free survival—meaning patients were still alive without worsening of disease—and overall survival in people previously treated with Nexavar (sorafenib).
For more...
https://www.hepmag.com/article/fda-approves-new-targeted-treatment-liver-cancer